BioAgilytix announces acquisition of Boston-based clinical research organisation Cambridge Biomedical

Highly complementary transaction strengthens BioAgilytix’s ability to support all phases of biologics development; adds to growing cell and gene therapy expertise; increases laboratory capacity; expands team of seasoned bioanalytical scientists; broadens geographic reach. London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, acknowledges the announcement from its… read more

Subscribe to our email alerts

Email updates